Physician profile
Manreet Basra
NPI 1114157484
$7,439.68
in general payments reported to CMS, 2019-2025
34 companies · $652 in 2025
The $652 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,573 · 2020: $237 · 2021: $668 · 2022: $1,080 · 2023: $2,573 · 2024: $657 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,095 · Travel and Lodging: $767 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,095.20 |
| Travel and Lodging | $766.72 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,881.91 | 2019-2023 | Mitraclip |
| Boston Scientific Corporation | $1,428.81 | 2019-2025 | Watchman Flx, Watchman Access System, Axios |
| Janssen Pharmaceuticals, INC | $497.28 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $464.18 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $459.89 | 2019-2024 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $412.82 | 2019-2024 | Jardiance |
| Medtronic, INC. | $337.31 | 2021-2025 | Aurora Ev-Icd Mri Surescan, Reveal Linq, Linq II |
| Sanofi-Aventis U.S. LLC | $278.91 | 2019-2022 | |
| Amgen INC. | $238.07 | 2019-2023 | Repatha |
| Pfizer INC. | $174.94 | 2019-2024 | |
| Philips North America LLC | $167.44 | 2023-2025 | (5044) Mcot, Ambulatory Monitoring & Diagnostics Undivided, Mcot |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $120.54 | 2019-2023 | Lifevest |
| Abbvie INC. | $120.05 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $84.52 | 2023 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals Lp | $82.75 | 2019-2024 | Farxiga |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $81.98 | 2023 | Optimizer |
| Lexicon Pharmaceuticals, INC. | $78.78 | 2023-2024 | Inpefa |
| Angiodynamics, INC. | $69.25 | 2019 | |
| Novo Nordisk INC | $65.49 | 2021-2022 | |
| Edwards Lifesciences Corporation | $64.15 | 2023-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Merck Sharp & Dohme LLC | $58.71 | 2022-2023 | Verquvo |
| Chiesi USA, INC. | $39.09 | 2019-2023 | Kengreal, Cleviprex |
| Bayer Healthcare Pharmaceuticals INC. | $31.30 | 2019-2025 | |
| Resmed Corp | $25.34 | 2022 | |
| Heartflow, INC. | $22.54 | 2024 | |
| Astellas Pharma US INC | $20.19 | 2019 | |
| Cook Medical LLC | $19.40 | 2023 | Zilver Ptx |
| Regeneron Healthcare Solutions, INC. | $18.30 | 2021 | |
| Kiniksa Pharmaceuticals, Ltd. | $17.26 | 2022 | |
| Tactile Systems Technology INC | $16.93 | 2023 | Flexitouch Plus, Entre Plus |
| Alnylam Pharmaceuticals INC. | $16.85 | 2020 | |
| Amarin Pharma, INC. | $15.19 | 2019 | |
| United Therapeutics Corporation | $15.18 | 2024 | Tyvaso |
| Scpharmaceuticals INC. | $14.33 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manreet Basra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.